List of Contents

Pediatric Vaccines Market Size, Share, and Trends 2024 to 2033

Pediatric Vaccines Market (By Type: Monovalent, Multivalent; By Technology: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines; By Indication: Varicella, Human Papilloma Virus, Measles, Mumps & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Diphtheria, Pertussis & Tetanus, Influenza, Other Indications) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 4527
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pediatric Vaccines Market 

5.1. COVID-19 Landscape: Pediatric Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pediatric Vaccines Market, By Type

8.1. Pediatric Vaccines Market, By Type, 2024-2033

8.1.1 Monovalent

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Multivalent

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Pediatric Vaccines Market, By Technology

9.1. Pediatric Vaccines Market, By Technology, 2024-2033

9.1.1. Live Attenuated Vaccines

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Inactivated Vaccines

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Toxoid Vaccines

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Pediatric Vaccines Market, By Indication 

10.1. Pediatric Vaccines Market, By Indication, 2024-2033

10.1.1. Varicella

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Human Papilloma Virus

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Measles, Mumps & Rubella

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Meningococcal Disease

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Pneumococcal Disease

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Polio

10.1.6.1. Market Revenue and Forecast (2021-2033)

10.1.7. Rotavirus

10.1.7.1. Market Revenue and Forecast (2021-2033)

10.1.8. Diphtheria, Pertussis & Tetanus

10.1.8.1. Market Revenue and Forecast (2021-2033)

10.1.9. Influenza

10.1.9.1. Market Revenue and Forecast (2021-2033)

10.1.10. Other Indications

10.1.10.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Pediatric Vaccines Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, By Type (2021-2033)

11.1.2. Market Revenue and Forecast, By Technology (2021-2033)

11.1.3. Market Revenue and Forecast, By Indication (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.1.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.1.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.1.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.1.5.3. Market Revenue and Forecast, By Indication (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, By Type (2021-2033)

11.2.2. Market Revenue and Forecast, By Technology (2021-2033)

11.2.3. Market Revenue and Forecast, By Indication (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.2.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.2.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.2.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.2.5.3. Market Revenue and Forecast, By Indication (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, By Type (2021-2033)

11.2.6.2. Market Revenue and Forecast, By Technology (2021-2033)

11.2.6.3. Market Revenue and Forecast, By Indication (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, By Type (2021-2033)

11.2.7.2. Market Revenue and Forecast, By Technology (2021-2033)

11.2.7.3. Market Revenue and Forecast, By Indication (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, By Type (2021-2033)

11.3.2. Market Revenue and Forecast, By Technology (2021-2033)

11.3.3. Market Revenue and Forecast, By Indication (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.3.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.3.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.3.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.3.5.3. Market Revenue and Forecast, By Indication (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, By Type (2021-2033)

11.3.6.2. Market Revenue and Forecast, By Technology (2021-2033)

11.3.6.3. Market Revenue and Forecast, By Indication (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, By Type (2021-2033)

11.3.7.2. Market Revenue and Forecast, By Technology (2021-2033)

11.3.7.3. Market Revenue and Forecast, By Indication (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.4.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.4.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.4.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.4.5.3. Market Revenue and Forecast, By Indication (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, By Type (2021-2033)

11.4.6.2. Market Revenue and Forecast, By Technology (2021-2033)

11.4.6.3. Market Revenue and Forecast, By Indication (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, By Type (2021-2033)

11.4.7.2. Market Revenue and Forecast, By Technology (2021-2033)

11.4.7.3. Market Revenue and Forecast, By Indication (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.5.3. Market Revenue and Forecast, By Indication (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, By Type (2021-2033)

11.5.4.2. Market Revenue and Forecast, By Technology (2021-2033)

11.5.4.3. Market Revenue and Forecast, By Indication (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, By Type (2021-2033)

11.5.5.2. Market Revenue and Forecast, By Technology (2021-2033)

11.5.5.3. Market Revenue and Forecast, By Indication (2021-2033)

Chapter 12. Company Profiles

12.1. Serum Institute of India Pvt. Ltd. 

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Sanofi Aventis

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. CSL Limited

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AstraZeneca Plc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Merck & Co., Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GlaxoSmithKline Plc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Pfizer Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Emergent BioSolutions Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Novavax, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Johnson & Johnson

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global pediatric vaccines market size is expected to increase USD 105.69 billion by 2033 from USD 59.13 billion in 2023.

The pediatric vaccines market is anticipated to grow at a CAGR of over 5.98% between 2024 and 2033

The major players operating in the pediatric vaccines market are Serum Institute of India Pvt. Ltd., Sanofi Aventis, CSL Limited, AstraZeneca Plc., Merck & Co., Inc., GlaxoSmithKline Plc., Pfizer Inc., Emergent BioSolutions Inc., Novavax, Inc., Johnson & Johnson, and Others.

The driving factors of the pediatric vaccines market are the rising prevalence of pediatric diseases and rising awareness of child health.

North America region will lead the global pediatric vaccines market during the forecast period 2024 to 2033.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us